Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | CSF1R | P07333 | 8/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | HAT1 | O14929 | 2/20 | 0.36 |
| ▸ | EP300 | Q09472 | 2/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19902655 | 0.91 | USP30 (0.56) | USP30ROCK1ROCK2CSF1RHAT1 | |
| SCHEMBL17452985 | 0.91 | ROCK2 (0.51) | USP30PRMT5WDR77ROCK1ROCK2 | |
| SCHEMBL19902637 | 0.88 | USP30 (0.46) | USP30PRMT5WDR77ROCK1ROCK2 | |
| SCHEMBL19902392 | 0.88 | ROCK1 (0.43) | USP30ROCK1ROCK2CSF1RTGFBR1 | |
| SCHEMBL19902725 | 0.85 | ROCK1 (0.38) | USP30ROCK1ROCK2CSF1RTGFBR1 | |
| SCHEMBL19902648 | 0.85 | ROCK1 (0.43) | USP30ROCK1ROCK2CSF1RTGFBR1 | |
| SCHEMBL19902368 | 0.85 | ROCK1 (0.49) | USP30PRMT5WDR77ROCK1ROCK2 | |
| SCHEMBL19902485 | 0.85 | ROCK1 (0.47) | USP30ROCK1ROCK2TGFBR1 | |
| SCHEMBL19902532 | 0.84 | DYRK1A (0.46) | USP30ROCK1ROCK2 | |
| SCHEMBL19902410 | 0.84 | ROCK1 (0.45) | ROCK1ROCK2CSF1RCCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | USP30 3527/4885PRMT5 1304/4885WDR77 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.